Zacks Investment Research | Jan 02, 2018 10:03PM ET
Shares of Trevena, Inc. (NASDAQ:TRVN) rallied almost 24.5% in after-market trading on Jan 2, following the company’s announcement that the FDA has accepted the new drug application (“NDA”) for its pain therapy, Olinvo injection. Olinvo is an opioid-based analgesic administered intravenous and also the first G protein biased ligand of the mu receptor.
The company expects a decision from the FDA in the fourth quarter of 2018.
Shares of Trevena have lost 71.3% in the past year, significantly underperforming the industry ’s gain of 2.8%. A potential approval from the FDA can give a boost to the stock.
The NDA included data from three phase III studies – APOLLO-1, APOLLO-2 and ATHENA – and a phase II study, which evaluated Olinvo in patients with moderate-to-severe acute pain.
Data from phase II & ATHENA studies have shown that Olinvo has achieved rapid and powerful analgesic efficacy and a wider therapeutic window versus morphine. Data from APOLLO-1 and APOLLO-2 also showed that the drug achieved statistically greater analgesic efficacy compared to placebo.
Trevena does not have any approved product in its portfolio and did not record any revenues in the third quarter of 2017.
The company believes that upon a potential approval it will incur significant expenses for commercialization of the drug. The company will have to seek various ways to raise funds. Also, it will face competition from currently marketed drugs, which include AcelRx Pharmaceuticals, Inc.’s (NASDAQ:ACRX) Dsuvia and Mallinckrodt Public Limited Company’s (NYSE:MNK) Exalgo.
Meanwhile, the company is also developing two G protein biased ligand candidates — TRV250, as a non-narcotic treatment for migraine and TRV734 for moderate-to-severe acute and chronic pain.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.